NASDAQ:PASG Passage Bio (PASG) Stock Forecast, Price & News $0.67 -0.01 (-0.87%) (As of 12:46 PM ET) Add Compare Share Share Today's Range$0.66▼$0.6950-Day Range$0.67▼$1.0152-Week Range$0.65▼$1.92Volume82,013 shsAverage Volume197,478 shsMarket Capitalization$36.71 millionP/E RatioN/ADividend YieldN/APrice Target$8.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Passage Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,143.2% Upside$8.40 Price TargetShort InterestHealthy0.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 3 Articles This WeekInsider TradingAcquiring Shares$518,601 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.01) to ($1.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.52 out of 5 starsMedical Sector124th out of 963 stocksBiological Products, Except Diagnostic Industry14th out of 159 stocks 3.5 Analyst's Opinion Consensus RatingPassage Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.40, Passage Bio has a forecasted upside of 1,143.2% from its current price of $0.68.Amount of Analyst CoveragePassage Bio has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.61% of the float of Passage Bio has been sold short.Short Interest Ratio / Days to CoverPassage Bio has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Passage Bio has recently increased by 5.30%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPassage Bio does not currently pay a dividend.Dividend GrowthPassage Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PASG. Previous Next 2.5 News and Social Media Coverage News SentimentPassage Bio has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Passage Bio this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for PASG on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows6 people have added Passage Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Passage Bio insiders have bought 5,045.36% more of their company's stock than they have sold. Specifically, they have bought $518,601.00 in company stock and sold $10,079.00 in company stock.Percentage Held by Insiders14.10% of the stock of Passage Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.56% of the stock of Passage Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Passage Bio are expected to grow in the coming year, from ($2.01) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Passage Bio is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Passage Bio is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPassage Bio has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Passage Bio (NASDAQ:PASG) StockPassage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More PASG Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PASG Stock News HeadlinesSeptember 25, 2023 | benzinga.comPassage Bio to Present at Chardan's 7th Annual Genetic Medicines ConferenceSeptember 25, 2023 | finance.yahoo.comPassage Bio to Present at Chardan’s 7th Annual Genetic Medicines ConferenceSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 5, 2023 | finance.yahoo.comIs Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?August 11, 2023 | finance.yahoo.comLab Notes: Almac Group starts work on $65M Montco expansion expected to create 355 jobsAugust 9, 2023 | nasdaq.comChardan Capital Maintains Passage Bio (PASG) Buy RecommendationAugust 7, 2023 | fr.investing.comLe BPA de Passage Bio a dépassé les attentes de 0,03$, le CA conforme aux prévisionsAugust 7, 2023 | seekingalpha.comPassage Bio GAAP EPS of -$0.44 beats by $0.03September 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 7, 2023 | finance.yahoo.comPassage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 StudyAugust 7, 2023 | finance.yahoo.comPassage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business HighlightsJuly 31, 2023 | finance.yahoo.comPassage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of DirectorsJuly 30, 2023 | finance.yahoo.comPassage Bio, Inc. (PASG) stock forecast and price targetJuly 24, 2023 | bizjournals.comPassage Bio reduces staff by 26% in latest round of job cutsJuly 6, 2023 | msn.comPassage Bio (PASG) Price Target Increased by 12.09% to 8.33June 30, 2023 | benzinga.comPassage Bio 10% Owner Trades Company's StockJune 30, 2023 | benzinga.comPassage Bio And 2 Other Penny Stocks Insiders Are Aggressively BuyingJune 10, 2023 | finance.yahoo.comPASG - Passage Bio, Inc.June 5, 2023 | finance.yahoo.comPassage Bio to Present at Goldman Sachs 44th Annual Global Healthcare ConferenceMay 19, 2023 | seekingalpha.comPASG Passage Bio, Inc.May 12, 2023 | msn.comRaymond James Maintains Passage Bio (PASG) Outperform RecommendationMay 12, 2023 | msn.comRecap: Passage Bio Q1 EarningsMay 11, 2023 | fr.investing.comLe BPA de Passage Bio a manqué les attentes de 0,11$, le CA conforme aux prévisionsMay 11, 2023 | markets.businessinsider.comGoldman Sachs Reaffirms Their Hold Rating on Passage Bio (PASG)May 11, 2023 | finance.yahoo.comPassage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business HighlightsMay 4, 2023 | finance.yahoo.comPassage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship AwardApril 17, 2023 | benzinga.comPassage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing SummitSee More Headlines Receive PASG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address PASG Company Calendar Last Earnings8/07/2023Today9/27/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PASG CUSIPN/A CIK1787297 Webwww.passagebio.com Phone267-866-0311FaxN/AEmployees85Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.40 High Stock Price Forecast$11.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+1,143.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-136,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-60.01% Return on Assets-48.67% Debt Debt-to-Equity RatioN/A Current Ratio7.73 Quick Ratio7.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.69 per share Price / Book0.18Miscellaneous Outstanding Shares54,810,000Free Float47,083,000Market Cap$37.04 million OptionableNot Optionable Beta1.00 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. William Chou M.D. (Age 50)Pres, CEO & Director Comp: $395.43kMr. Edgar B. Cale Esq. (Age 59)J.D., Gen. Counsel & Company Sec. Comp: $674.36kDr. James M. Wilson M.D. (Age 68)Ph.D., Co-Founder & Chief Scientific Advisor Ms. Kathleen Borthwick (Age 47)Sr. VP of Fin., Principal Accounting Officer & Interim CFO Mr. Stuart M. HendersonSr. VP of Corp. Devel. & Investor RelationsGregory FuestVP of Global Commercial Strategy & MarketingDr. Mark Forman M.D. (Age 59)Ph.D., Chief Medical Officer Dr. Desiree Luthman D.D.S.Sr. VP of Global Regulatory AffairsEden FucciSr. VP of Technical OperationsMore ExecutivesKey CompetitorsMiromatrix MedicalNASDAQ:MIROAchilles TherapeuticsNASDAQ:ACHLIN8bioNASDAQ:INABCortexymeNASDAQ:CRTXCognition TherapeuticsNASDAQ:CGTXView All CompetitorsInsiders & InstitutionsRBF Capital LLCBought 32,000 shares on 8/15/2023Ownership: 0.261%Renaissance Technologies LLCBought 14,195 shares on 8/11/2023Ownership: 1.786%Pale Fire Capital SEBought 98,662 shares on 8/11/2023Ownership: 0.180%Simplex Trading LLCSold 500 shares on 8/4/2023Ownership: 0.000%Simona KingSold 11,453 sharesTotal: $10,078.64 ($0.88/share)View All Insider TransactionsView All Institutional Transactions PASG Stock - Frequently Asked Questions Should I buy or sell Passage Bio stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PASG shares. View PASG analyst ratings or view top-rated stocks. What is Passage Bio's stock price forecast for 2023? 5 brokers have issued 1-year price targets for Passage Bio's stock. Their PASG share price forecasts range from $5.00 to $11.00. On average, they predict the company's stock price to reach $8.40 in the next year. This suggests a possible upside of 1,143.2% from the stock's current price. View analysts price targets for PASG or view top-rated stocks among Wall Street analysts. How have PASG shares performed in 2023? Passage Bio's stock was trading at $1.38 on January 1st, 2023. Since then, PASG stock has decreased by 51.0% and is now trading at $0.6757. View the best growth stocks for 2023 here. When is Passage Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our PASG earnings forecast. How were Passage Bio's earnings last quarter? Passage Bio, Inc. (NASDAQ:PASG) announced its quarterly earnings results on Monday, August, 7th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.03. What other stocks do shareholders of Passage Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include Alector (ALEC), NVIDIA (NVDA), Advanced Micro Devices (AMD), DocuSign (DOCU), Intel (INTC), Alteryx (AYX), Gossamer Bio (GOSS), JD.com (JD), Micron Technology (MU) and Black Diamond Therapeutics (BDTX). When did Passage Bio IPO? (PASG) raised $126 million in an initial public offering (IPO) on Friday, February 28th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Chardan was co-manager. What is Passage Bio's stock symbol? Passage Bio trades on the NASDAQ under the ticker symbol "PASG." Who are Passage Bio's major shareholders? Passage Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include BML Capital Management LLC (3.77%), Renaissance Technologies LLC (1.79%), RBF Capital LLC (0.26%), Pale Fire Capital SE (0.18%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Alexandros Fotopoulos, Bruce A Goldsmith, Gary Romano, Jill M Quigley, Orbimed Advisors Llc, Richard Steven Morris, Sandip Kapadia and Simona King. View institutional ownership trends. How do I buy shares of Passage Bio? Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Passage Bio's stock price today? One share of PASG stock can currently be purchased for approximately $0.68. How much money does Passage Bio make? Passage Bio (NASDAQ:PASG) has a market capitalization of $37.04 million. The company earns $-136,130,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. How can I contact Passage Bio? Passage Bio's mailing address is TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103. The official website for the company is www.passagebio.com. The company can be reached via phone at 267-866-0311 or via email at investors@passagebio.com. This page (NASDAQ:PASG) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.